接受与未接受rhPTH(1-84)治疗的甲状旁腺功能减退症患者五年估计肾小球滤过率
该回顾性分析比较了69例来自4项开放标签长期试验、接受rhPTH(1-84)治疗的慢性甲状旁腺功能减退症患者与53例来自Geisinger医疗数据库、未接受rhPTH(1-84)的历史对照患者的eGFR变化。5年随访结束时,rhPTH(1-84)组平均eGFR升高2.8 mL/min/1.73 m2,对照组平均eGFR下降8.0 mL/min/1.73 m2;校正模型中两组年eGFR变化差异为1.7 mL/min/1.73 m2/年(P = 0.009)。
要点
- rhPTH(1-84)组5年末平均eGFR升高2.8 mL/min/1.73 m2,对照组下降8.0 mL/min/1.73 m2。
- 校正模型中两组年eGFR变化差异为1.7 mL/min/1.73 m2/年(P = 0.009)。
- 基线时两组人口学特征和eGFR相似,但rhPTH(1-84)组糖尿病和心脏疾病比例较低。
核心结论
- 接受rhPTH(1-84)治疗的慢性HypoPT患者eGFR在5年以上得以保持,而未接受rhPTH(1-84)者eGFR下降。
研究设计与样本
- 回顾性分析,rhPTH(1-84)队列为来自4项开放标签长期试验(NCT00732615、NCT01268098、NCT01297309和NCT02910466)的69例慢性HypoPT患者,历史对照队列为来自Geisinger医疗数据库(2004年1月至2016年6月)的53例未接受rhPTH(1-84)的慢性HypoPT患者。
主要发现
- 随访结束时,rhPTH(1-84)组平均eGFR升高2.8 mL/min/1.73 m2,对照组平均eGFR下降8.0 mL/min/1.73 m2。
- 校正模型中,rhPTH(1-84)组与对照组年eGFR变化差异为1.7 mL/min/1.73 m2/年(P = 0.009)。
- 基线时两组人口学特征和eGFR相似,但rhPTH(1-84)组糖尿病和心脏疾病比例较低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Chronic hypoparathyroidism (HypoPT) is conventionally managed with oral calcium and active vitamin D. Recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) is a therapy targeting the pathophysiology of HypoPT by replacing parathyroid hormone. OBJECTIVE: To compare changes in the estimated glomerular filtration rate (eGFR) in patients with chronic HypoPT receiving or not receiving rhPTH(1-84) during a 5-year period. DESIGN/SETTING: A retrospective analysis of patients with chronic HypoPT treated with or without rhPTH(1-84). PATIENTS: Sixty-nine patients with chronic HypoPT from 4 open-label, long-term trials (NCT00732615, NCT01268098, NCT01297309, and NCT02910466) composed the rhPTH(1-84) cohort and 53 patients with chronic HypoPT not receiving rhPTH(1-84) from the Geisinger Healthcare Database (01/2004-06/2016) composed the historical control cohort. INTERVENTIONS: The rhPTH(1-84) cohort (N = 69) received rhPTH(1-84) therapy; the historical control cohort (N = 53) did not receive rhPTH(1-84). MAIN OUTCOME MEASURES: Changes in eGFR from baseline during a 5-year follow-up were examined in multivariate regression analyses. RESULTS: At baseline, demographic characteristics and eGFR were similar between cohorts, though the proportions with diabetes and cardiac disorders were lower in the rhPTH(1-84) cohort. At the end of follow-up, mean eGFR increased by 2.8 mL/min/1.73 m2 in the rhPTH(1-84) cohort, while mean eGFR fell by 8.0 mL/min/1.73 m2 in the control cohort. In the adjusted model, the difference in the annual eGFR change between the rhPTH(1-84) cohort and the control cohort was 1.7 mL/min/1.73 m2 per year (P = 0.009). CONCLUSIONS: Estimated glomerular filtration rate was preserved for over 5 years among patients with chronic HypoPT receiving rhPTH(1-84) treatment, contrasting with an eGFR decline among those not receiving rhPTH(1-84).
引用
- Chen KS, Gosmanova EO, Curhan GC, et al. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). J Clin Endocrinol Metab. 2020. PMID: 32738041. doi:10.1210/clinem/dgaa490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。